Mortality associated with systemic candidiasis in children.
The purpose of this study was to determine factors associated with an increased risk of mortality due to systemic Candida infections in children hospitalized at our tertiary care facility. A total of 71 cases of Candida bloodstream infections were identified over a 2-year period. The attack rate was 47 cases of candidemia per 10,000 discharges and the case fatality rate was 46.5%. Sixty-one cases occurred in infants under 2 years; 27 were newborns (38%). Using logistic regression analysis, we evaluated the independent effects of potential risk factors for death due to candidemia. Three factors were associated with the subsequent risk for death due to systemic candida infection: malnutrition (OR = 4.3; 95% CI 1.2-14.8), prior surgery (OR = 3.8; 95% CI 1.2-13.2), and the number of days between the first positive candida blood culture and the onset of antifungal treatment (OR = 1.12; 95% CI 1.06-1.25). Newborns showed an almost three times greater risk of death due to candidemia as compared to other age groups, but this association was only marginally significant (OR = 2.8; 95% CI 0.9-9.3). There was no difference in the rate of candidemia between the 2 years of the study; however, the observed mortality declined significantly from 65% in year one to 20% in year two (p = 0.02). The major finding of this study was to observe that for every day treatment was delayed the risk of death increased significantly. Thus, this study provides support for empirical antifungal therapy early in the course of suspected systemic candidiasis in order to improve survival among children.
Pacheco-Ríos
A
A
Department of Infectious Diseases, Hospital Infantil de México, Federico Gómez, México, D.F.
Avila-Figueroa
C
C
Nobigrot-Kleinman
D
D
Santos
J I
JI
D000293:Adolescent; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000401:mortality*; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D003428:Cross Infection / Q000401:mortality*; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000401:mortality*; D006776:Hospitals, Pediatric / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007226:Infant Mortality; D007231:Infant, Newborn; D008297:Male; D008800:Mexico / Q000453:epidemiology; D009748:Nutrition Disorders / Q000453:epidemiology; D011183:Postoperative Complications / Q000401:mortality; D012307:Risk Factors; D013997:Time Factors
D000935:Antifungal Agents